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Abstract ING1b can stimulate cell cycle arrest, repair, senes-
cence, and apoptosis. The actions of ING1b are attributed to its
activation of the tumor suppressor p53. Here we investigate the
more subtle e¡ects of ING1b on the cell cycle and DNA damage
responses in the absence of p53. To this end, we have generated
isogenic cell lines that expressed ING1b and p53 either individ-
ually or in combination under the control of inducible pro-
moters. A ¢ve- to 10-fold induction of ING1b over the endog-
enous protein in a p53-null H1299 background slightly impairs
proliferation by increasing the doubling time byV10%. Signi¢-
cantly, ectopic expression of ING1b enhanced the G2/M DNA
damage checkpoint induced by adriamycin. We demonstrated
that the DNA damage-induced cell death mediated by the co-
operation between ING1b and p53 was more prominent than by
the individual proteins alone. In adriamycin-treated cells, p53
was stabilized and induced the expression of p21CIP1=WAF1, but
the expression of ING1b was not a¡ected. The exact targets of
ING1b in the p53-null background are not known, but we dem-
onstrated that the transcriptional activities of other members of
the p53 family, p63K and p73K, could be activated by ING1b.
These data indicate that ING1 has a subtle antiproliferative
e¡ect even in the absence of p53, and ING1b enhances the
DNA damage responses through p53-dependent and -indepen-
dent mechanisms.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
ING1 was ¢rst identi¢ed as a candidate tumor suppressor
through a functional screening based on selection of gene
fragments that can block the activity of tumor suppressors
and cause transformation [1]. ING1 encodes a 47-kDa protein
(ING1a), an alternatively spliced 33-kDa protein (ING1b),
and a 24-kDa protein (ING1c) from an internal initiation
site [2,3]. The three isoforms have di¡erent N-terminal regions
but share a common C-terminal PHD ¢nger (a C4HC3-type
zinc ¢nger that is implicated in transcriptional regulation).
ING1b and ING1c are the major isoforms expressed in hu-
man tissues [2], and there are indications that the di¡erent
isoforms may have di¡erent functions [4].
ING1 has been implicated to play a role in cell cycle con-
trol, apoptosis, and senescence. ING1 is upregulated in the
S phase and in senescent human ¢broblasts, and antisense
ING1 extends the proliferative lifespan of normal human
¢broblasts [5]. ING1b is upregulated during apoptosis, and
overexpression of ING1b inhibits cell growth and enhances
apoptosis [1,6,7]. Conversely, expression of ING1 antisense
constructs promotes transformation [1] and protects against
apoptosis [6]. In this connection, the anti-apoptotic protein
A1 can bind to mouse ING1 and inhibit the pro-apoptotic
e¡ects of ING1 [8].
The expression of ING1 is not regulated by DNA damage
in ¢broblasts, but ING1 is induced in keratinocytes and mel-
anoma cell lines by UV irradiation [9,10]. After UV irradia-
tion, ING1b shifts from the nucleoplasm to the nucleolus [11],
and enhances p53-dependent repair [9] and apoptosis [12].
Possibly related to these functions, ING1b is found to asso-
ciate with GADD45 [9] and with PCNA after UV irradiation
[13].
The growth inhibitory and apoptosis-inducing functions of
ING1 appear to involve the tumor suppressor p53 [14,15].
Physical interaction between ING1 and p53 was demonstrated
by co-immunoprecipitation [14]. Moreover, the transcriptional
activities of p53 are enhanced by ING1, but are eliminated by
antisense ING1 constructs [14]. Our laboratory found that
one mechanism by which ING1b stimulates the activity of
p53 is by increasing the stability of p53 through disruption
of the p53^MDM2 interaction [16]. Like ING1, other mem-
bers of the ING family, ING2 [17,18] and ING3 [19], also
negatively regulate cell growth and survival by activation of
p53. But unlike ING1b, ING2 activates p53 by increasing the
acetylation of p53 at Lys-382 [17]. Similarly, ING4 and ING5
enhance the acetylation of p53 at Lys-382 and induction of
apoptosis in a p53-dependent manner [20]. Interestingly, the
PHD domain of ING2 acts as a nuclear phosphoinositide
receptor, and this interaction regulates the ability of ING2
to activate p53 and p53-dependent apoptotic pathways [21].
ING1 has been implicated in chromatin remodeling and
transcriptional control. Three proteins in yeast that share sig-
ni¢cant sequence identity with ING1 (Yng1p, Yng2p, and
Pho23p) are associated with histone acetyltransferase (HAT)
complexes [22]. Yng1p and Yng2p are components of the
NuA3 and NuA4 HAT complexes respectively [23^25]. In
human cells, ING1b is associated with the Sin3-containing
histone deacetylases (HDAC) through direct interaction with
the Sin3 component SAP30 [26,27]. In another report, it was
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found that while complexes containing human ING1b possess
HAT activity, the isoform ING1a binds HDAC1 and inhibits
histone acetylation [28].
Although ING1 is rarely mutated, its expression and local-
ization are altered in several cancers. Several missense muta-
tions of ING1 were found within the PHD ¢nger domain and
the nuclear localization motif in head and neck squamous cell
carcinoma [29,30]. ING1 expression is reduced in breast can-
cer [31,32], gastric cancer [33], and lymphoid malignancies
[34]. Finally, the subcellular localization of ING1b is shifted
from the nucleus to the cytoplasm in melanoma [35] and acute
lymphoblastic leukemia [36].
The p53-dependent roles of ING1b in antiproliferation are
well established. However, induction of ING1b after DNA
damage does not require p53 [10], and it is not clear how
ING1b a¡ects cell proliferation in the absence of p53. Using
isogenic cell lines, we have examined the e¡ects of ING1b
expression on cell cycle progression and DNA damage re-
sponses in the presence or absence of p53.
2. Materials and methods
2.1. Materials
All reagents were obtained from Sigma-Aldrich (St. Louis, MO,
USA) unless stated otherwise.
2.2. DNA constructs
FLAG-ING1b in pUHD-P1 and p53 in pLINX were constructed as
described previously [16]. The EcoRI^SalI fragment from FLAG-
ING1b in pUHD-P1 was ligated into pGEX-KG to produce GST-
ING1b in pGEX-KG. The ClaI fragment from p53 in pLINX was put
into pRevTRE2 (Clontech, Palo Alto, CA, USA). The BamHI frag-
ment containing the puromycin-resistant gene (a gift from Katsumi
Yamashita, Kanazawa University, Japan) was put into BamHI-cut
FLAG-ING1b in pUHD-P1 to produce FLAG-ING1b in pUHD-
P1/PUR. HA-tagged simian p73K in pcDNA3, p53 in pRcCMV,
and p63K in pRc/CMV were obtained from sources as previously
described [37].
2.3. Cell culture
H1299 (non-small cell lung carcinoma) [38] was obtained from the
American Type Culture Collection (Rockville, MD, USA). Cells were
grown in Dulbecco’s modi¢ed Eagle’s medium supplemented with
10% (v/v) fetal bovine serum (Invitrogen Life Technologies, Carlsbad,
CA, USA) in a humidi¢ed incubator at 37‡C in 5% CO2. Cells were
transfected with the calcium phosphate precipitation method [39]. UV
treatment and cell-free extracts were as described previously [40]. Un-
less stated otherwise, cells were treated with the following reagents at
the indicated ¢nal concentrations: adriamycin (ADR; 0.02 Wg/ml),
doxycycline (DOX; 1 Wg/ml), G418 (100 Wg/ml), hygromycin (100
Wg/ml), nocodazole (0.1 Wg/ml), and puromycin (1 Wg/ml).
Inducible ING1b/H1299 cell lines were produced by cotransfection
of FLAG-ING1b in pUHD-P1/PUR and pLINX constructs (a gift
from Tony Hunter, Salk Institute, La Jolla, CA, USA) into H1299.
The cells were then selected in medium supplemented with puromycin,
G418, and DOX. Inducible p53/H1299 cell lines were produced by
transfection of p53 in pLINX into H1299, followed by selection in
medium supplemented with G418 and DOX. Inducible p53+ING1b/
H1299 cell lines were produced by transfection of p53 in pRevTRE2
into ING1b/H1299, followed by selection in medium supplemented
with hygromycin and DOX. After about 3 weeks of selection, indi-
vidual colonies were isolated and expanded. The expression of FLAG-
ING1b or p53 was analyzed after growing cells in medium in the
presence or absence of DOX for 24 h. The established cell lines
were propagated in the presence of DOX but without other antibiotic
selection. The expression of ING1b and/or p53 was constantly moni-
tored because they were frequently lost during passage.
2.4. Cell growth analysis and £ow cytometry
Trypan blue exclusion analysis and £ow cytometry analysis after
propidium iodide staining were performed as described [41]. Cell
growth was measured by seeding V104 cells per 60-mm plate and
counting the attached cells in the same randomly selected areas
(2-mm-diameter circles ¢xed at the bottom of the plate) every 24 h
using a light microscope. The population doubling time was estimated
by plotting the log of cell number against time. For clonogenic sur-
vival assays, 500 cells were seeded per 10-cm plate either in the pres-
ence or absence of DOX. After 12 h, the cells were treated with the
indicated concentration of ADR (also called doxorubicin) or cisplatin
(CIS; cis-platinum(II)diammine dichloride) for 3 h. The cells were
then washed and fresh medium (with or without DOX) was added
and replenished every three days. After 2^3 weeks, colonies were ¢xed
with methanol:acetic acid (2:1 v/v) and visualized by staining with 2%
w/v crystal violet in 20% methanol.
2.5. Expression and puri¢cation of recombinant proteins and binding
assays
Expression of GST-tagged proteins in bacteria and puri¢cation with
glutathione (GSH)-agarose chromatography were as described previ-
ously [42]. Coupled transcription^translation reactions in the presence
of [35S]methionine in rabbit reticulocyte lysate were performed as in-
structed by the manufacturer (Promega, Madison, WI, USA). Binding
assays were as described elsewhere [43].
2.6. Luciferase and L-galactosidase assays
Luciferase assays and L-galactosidase assays were performed ex-
actly as described previously [16].
2.7. Antibodies and immunological methods
Monoclonal antibodies M2 against FLAG tag were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Monoclonal antibodies YL1/2
against tubulin were gifts from Tim Hunt (Cancer Research UK,
South Mimms, UK). Goat antibodies raised against a C-terminal
peptide derived from ING1 (sc-7566), polyclonal antibodies against
p21CIP1=WAF1 (sc-397), monoclonal antibodies 4A4 against p63 (sc-
8431), and monoclonal antibodies DO-1 against p53 (sc-126) were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Immuno-
blotting was performed as described previously [40].
3. Results
3.1. Establishing inducible expression of ING1b in
p53-containing or -null backgrounds
An inducible expression system for FLAG-tagged ING1b
under the repression of DOX was created in the H1299 (p53-
null) background. Clones that had integrated the constructs
were isolated (herein designated ING1b/H1299). Fig. 1A
shows that several clones (#2 and #4) expressed FLAG-
ING1b in the absence of DOX. Background expression seen
in the presence of DOX is probably due to promoter leakage
and endogenous ING1b. We estimated by densitometry that
typically a ¢ve- to 10-fold induction of ING1b was obtained.
To create isogenic cell lines with or without p53, the p53
cDNA was introduced into both H1299 and ING1b/H1299.
Fig. 1B,C shows that p53/H1299 and p53+ING1b/H1299 ex-
pressed p53 with similar kinetics when DOX was removed. As
expected, ING1b was induced in the absence of DOX in
p53+ING1b/H1299, but remained constant (endogenous
ING1b) in p53/H1299. Immunoblotting for tubulin con¢rmed
uniform loading of lysates and p53 and/or ING1b expression
was speci¢cally controlled by DOX. Thus isogenic cell lines
that inducibly expressed p53, ING1b, or p53 and ING1b to-
gether were generated.
3.2. ING1b only slightly retards cell growth in the absence
of p53
To see whether ectopic expression of ING1b a¡ected pro-
liferation of H1299 cells, cell growth was examined in the
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presence or absence of DOX. We found that ING1b/H1299
grew only slightly slower than the parental H1299 if the ex-
pression of ING1b was suppressed (Fig. 2A). Cell prolifera-
tion was further reduced when ING1b was expressed. The
doubling time increased about 10% when ING1b was ex-
pressed. The subtle decrease in growth rate by ING1b was
further con¢rmed by trypan blue exclusion analysis (Fig.
2B). The growth of the parental H1299 cells was not a¡ected
by DOX (data not shown). Flow cytometry analysis indicated
that the percentage of cells with a G1 DNA content was
decreased when ING1b was induced (Figs. 3B and 4B), sug-
gesting that ING1b may cause a delay in S or G2/M. These
data indicate that expression of ING1b in the absence of p53
has a minor e¡ect on cell proliferation in H1299 cells.
3.3. ING1b enhances ADR-induced damage responses
We next examined the e¡ects of ING1b on the DNA dam-
age responses triggered by various DNA-damaging agents.
The chemotherapeutic agent ADR is a topoisomerase II poi-
son that ultimately generates double-stranded DNA breaks. A
relatively low dose of ADR was used in our experiments,
Fig. 1. Expression of ING1b and p53 in H1299 cells. A: ING1b/
H1299 cells were generated as described in Section 2. Individual
clones were isolated and grown in the presence (lanes 2, 4 and 6) or
absence (lanes 3, 5 and 7) of DOX for 24 h. Cell-free extracts were
prepared and were subjected to immunoblotting with antibodies
against ING1. Standards of FLAG-ING1b from transiently trans-
fected H1299 were loaded in lanes 1 and 8. The positions of the
molecular size markers (in kDa) are indicated on the left. B: p53/
H1299 cells were generated as described in Section 2, and were
grown in the presence or absence of DOX for 6 and 24 h as indi-
cated. Cell extracts were prepared and p53, ING1b, and tubulin
were detected by immunoblotting as indicated. Standards of p53
from transiently transfected H1299 were loaded in lane 1. Results
from two independent experiments are shown to indicate the consis-
tency of protein induction. C: p53+ING1b/H1299 cells were treated
exactly as in panel B.
Fig. 2. Ectopic expression of ING1b decreases cell growth.
A: H1299 or ING1b/H1299 cells were grown in medium in the
presence or absence of DOX as indicated. The number of attached
cells at di¡erent time points was counted as described in Section 2.
The cell numbers are normalized to the same starting level, and the
means and standard deviations of three independent experiments are
shown. The mean population doubling time and standard deviations
are shown on the right. B: ING1b/H1299 cells were grown in the
presence or absence of DOX for 16 h as indicated. The cells were
then treated with either control bu¡er or ADR for 24 h. The num-
ber of viable and trypan blue-stained dead cells was measured with
a hemeocytometer after trypan blue staining. The means and stan-
dard deviations from three independent experiments are shown.
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which was su⁄cient to cause a 50^70% reduction in popula-
tion doubling time in the parental H1299 cells. ADR induced
a similar reduction in proliferation of ING1b/H1299 when the
expression of ING1b was suppressed by DOX (Fig. 3A). In
contrast, proliferation was completely inhibited by ADR
when ING1b was expressed. The enhancement of ADR-in-
duced growth arrest by ING1b was also con¢rmed by trypan
blue exclusion analysis (Fig. 2B). As expected, ADR treat-
ment increased the population of cells in G2/M (Fig. 3B).
Remarkably, a prominent G2/M phase arrest was reproduci-
bly obtained when ADR was added in the presence of ING1b.
Taken together, these data show that overexpression of
ING1b in a p53-null background enhanced the G2/M arrest
induced by ADR.
To verify that the expression of ING1b was not a¡ected by
ADR, cell-free extracts were prepared and ING1b was de-
tected by immunoblotting. As expected, ING1b was induced
in cells after removal of DOX (Fig. 3C, lanes 1, 2, 5 and 6).
Importantly, the expression of ING1b was not a¡ected by
ADR (lanes 3 and 7), suggesting that the enhancement of
ADR-mediated cell cycle arrest was not simply due to an
increase in the ING1b level. Uniform loading of samples
was con¢rmed by immunoblotting for tubulin.
We found that the enhancement of DNA damage response
by ING1b was speci¢c for some types of DNA-damaging
agents and not extended to CIS and UV irradiation. The
growth rate of ING1b/H1299 was equally suppressed by
CIS treatment with or without the induction of ING1b (Fig.
4A). While a relatively low concentration of CIS (0.5 Wg/ml)
arrested H1299 predominantly in S and G2/M, a higher con-
centration (50 Wg/ml) triggered mainly G1 arrest (Fig. 4B).
Expression of ING1b did not a¡ect the cell cycle arrest caused
by either concentration of CIS. When H1299 was irradiated
with UV and progression through the subsequent mitosis was
blocked with nocodazole, there was only a modest increase in
cells remaining in G1 (Fig. 4C). This con¢rms that H1299 has
a weak G1 DNA damage checkpoint due to the lack of p53
pathway. Similar results were obtained with ING1b/H1299,
indicating that ING1b did not enhance the UV-induced
DNA damage responses. In mark contrast, re-introduction
of p53 into H1299 (p53/H1299) restored the G1 checkpoint
after UV irradiation. Taken together, these data show that
ING1b enhances the DNA damage responses to ADR but
not to CIS or UV.
3.4. ING1b moderately reduces cell survival
We next compare the antiproliferative e¡ects of ING1b in
p53-containing and p53-null backgrounds. For the p53/H1299
cells, the doubling time increased about two-fold when p53
was expressed (Fig. 5A). The p53+ING1b/H1299 cells grew
relatively slowly even in the presence of DOX, and prolifer-
ation was severely compromised when both recombinant pro-
teins were expressed (Fig. 5A). These cells did not immedi-
ately enter apoptosis because the level of recombinant p53
expression was only comparable to the basal p53 level in other
cell lines containing endogenous p53 (unpublished data).
6
Fig. 3. ING1b enhances ADR-induced DNA damage responses.
A: ING1b/H1299 cells were grown in medium in the presence or
absence of DOX. Control bu¡er or ADR was added on day 1 and
the number of cells was estimated every 24 h as described in Section
2. The means and standard deviations from three independent ex-
periments are shown. B: ING1b/H1299 cells were grown in the
presence or absence of DOX for 16 h. The cells were then treated
with either control bu¡er or ADR for 24 h as indicated. Cell cycle
distribution was analyzed by propidium iodide staining and £ow cy-
tometry. The percentages of cells in di¡erent cell cycle phases are
indicated. C: Expression of ING1b following ADR treatment.
ING1b/H1299 cells were grown in the presence or absence of DOX
for 16 h, and were then treated with control bu¡er or ADR for the
indicated time. Cell-free extracts were prepared, applied onto so-
dium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE), and immunoblotted with antibodies against ING1 or tubu-
lin. The positions of the molecular size markers (in kDa) are indi-
cated on the left.
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Proliferation of p53/H1299 and p53+ING1b/H1299 in the
absence of DOX was completely inhibited when the cells were
treated with ADR (Fig. 5B). It is signi¢cant that rather than
the same cell number after ADR treatment (as in ING1b/
H1299 cells in Fig. 3), there was a decrease in cell count in
the p53-containing cells. This suggests that there was an in-
crease in cell death in cells expressing p53. Loss of viability
was further con¢rmed by trypan blue exclusion analysis
(Fig. 5C). These data indicate that p53+ING1b/H1299 cells
were more sensitive to ADR than p53/H1299, which in turn
was more sensitive than ING1b/H1299 and H1299.
Induction of DNA damage in the p53 background was
accompanied by a stabilization of p53. Fig. 5D shows that
ADR and CIS increased the abundance of p53 in p53/
H1299 and p53+ING1b/H1299, but not in control cells lack-
ing p53. Moreover, one of the targets of p53, p21CIP1=WAF1,
was induced after DNA damage only in the presence of p53
(Fig. 5D). These results suggest that apart from p53 itself, the
mechanisms that lead to the stabilization of p53 after DNA
damage were intact in H1299.
Long-term growth potential of cells expressing ING1b and/
or p53 was examined by clonogenic survival assays. There was
a moderate reduction (V15%) in colony survival when
ING1b/H1299 cells were grown in the absence of DOX in
Fig. 4. ING1b does not a¡ect DNA damage responses to CIS and UV. A: ING1b/H1299 cells were grown in medium in the presence or ab-
sence of DOX. Control bu¡er or CIS (0.5 Wg/ml) was added on day 1 and the number of cells was estimated every 24 h as described in Section
2. The means and standard deviations from three independent experiments are shown. B: ING1b/H1299 cells were grown in the presence or ab-
sence of DOX for 16 h. The cells were then treated with either control bu¡er or CIS (0.5 Wg/ml or 50 Wg/ml) for 24 h as indicated. Cell cycle
distribution was analyzed by propidium iodide staining and £ow cytometry. The percentages of cells in di¡erent cell cycle phases are indicated.
C: H1299, ING1b/H1299, or p53/H1299 cells were grown in medium without DOX for 24 h. The medium was removed and the cells were ei-
ther mock treated or irradiated with 30 J/m2 of UV. Medium was added back and the cells were either mock treated or treated with nocoda-
zole to block the cells in G2/M. After 24 h, the cells were harvested and processed for £ow cytometry.
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comparison to cells that were continuously incubated in DOX
(Fig. 6, lanes 1 and 2). DOX had no e¡ect on clonogenic
survival in the parental H1299 cells (data not shown). A 50^
60% reduction of the number of colonies occurred when p53/
H1299 and p53+ING1b/H1299 were maintained in the ab-
sence of DOX. More detailed examination of the plates under
light microscopy indicated that the decrease in colony forma-
tion was likely to re£ect cell cycle arrest or cell death rather
than slower growth. These data suggest that expression of
ING1b had a small but signi¢cant e¡ect on clonogenic sur-
vival.
In a variation of the above experiments, p53/H1299 cells
were grown in the absence of DOX for three days, and
were then switched back to DOX-containing medium for
the remaining period of the experiment. Interestingly, a sim-
ilar decrease in the colony number was observed as if the cells
Fig. 5. ING1b and p53 enhanced ADR-induced cell death. A: p53/H1299 and p53+ING1b/H1299 cells were grown in medium in the presence
or absence of DOX. The parental H1299 cells were grown under the same conditions in the absence of DOX. The number of attached cells
was counted at di¡erent time points. The cell numbers are normalized to the same starting level, and the means and standard deviations of
three independent experiments are shown. The mean population doubling time and standard deviations are shown on the right. B: p53/H1299
and p53+ING1b/H1299 cells were grown in medium without DOX. Control bu¡er or ADR was added on day 1, and the number of attached
cells was counted at di¡erent time points. The means and standard deviations of three independent experiments are shown. C: p53/H1299
(lanes 1^4) and p53+ING1b/H1299 (lanes 5^8) cells were grown in medium with or without DOX for 16 h. The cells were then treated with
control bu¡er or ADR for 24 h and were analyzed by trypan blue staining. The means and standard deviations of viable and the trypan blue-
stained cells from three independent experiments are shown. D: Activation of p53 and p21CIP1=WAF1 by DNA damage. H1299, p53/H1299,
ING1b/H1299, and p53+ING1b/H1299 cells were grown in the absence of DOX and treated with bu¡er, ADR (0.2 Wg/ml), or CIS (5 Wg/ml)
for either 6 or 24 h as indicated. Cell-free extracts were prepared and p53, ING1, p21CIP1=WAF1, and tubulin were detected by immunoblotting.
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were grown continuously in the absence of DOX (Fig. 6, lane
7). These data suggest that when p53 is expressed transiently,
cells are not able to recover to re-enter the cell cycle. Intrigu-
ingly, p53+ING1b/H1299 could fully recover after growing in
medium without DOX for three days (lane 12). One possibil-
ity is that cells may enter a reversible cell cycle arrest state
when p53 and ING1b are expressed together. A less interest-
ing possibility is that the expression of p53 in p53+ING1b/
H1299 was not as robust as in p53/H1299, especially when the
expression of recombinant proteins decreased rapidly as the
passage number increased (see Fig. 5D, for example).
Although ING1b sensitized cells to short-term G2/M cell
cycle delay induced by ADR (Fig. 3), ING1b alone only
had a small impact on the long-term survival after ADR treat-
ment (Fig. 6, lanes 3 and 4). In contrast, the presence of p53
had a decisive e¡ect on clonogenic survival following ADR
treatment (lanes 8, 9, 13 and 14). These data suggest the
possibility that the interplay between p53, ING1b, and
DNA damage may govern whether the cell enters reversible
cell cycle arrest or cell death response pathways.
3.5. ING1b can activate p53-related transcription factors
One possible explanation of the growth inhibitory e¡ects of
ING1b in the absence of p53 is that ING1b may activate
other members of the p53 family. To see whether ING1b
could enhance the activities of p53-related proteins, their
transactivation of a MDM2 promoter-luciferase reporter
was analyzed in the presence or absence of ING1b (Fig.
7A). As expected, the transcriptional activity of p53 was
strongly activated by cotransfection with ING1b. We found
that the transcriptional activities of p73K and p63K were also
enhanced by ING1b, albeit not as robust as p53.
To see whether ING1b could physically interact with p53-
related proteins, a GST-ING1b fusion protein was expressed
in Escherichia coli and puri¢ed (Fig. 7B). As expected, [35S]-
labeled p53 produced in rabbit reticulocyte lysates was re-
tained by GST-ING1b, but not by control GST (Fig. 7C).
A slightly weaker interaction between p73K and GST-
ING1b was detected, but the background p73K signal was
higher. Similarly, recombinant p53 was co-immunoprecipi-
tated with FLAG-ING1b when the two proteins were co-ex-
pressed in H1299 cells (Fig. 7D). Although binding between
p63K and FLAG-ING1b was detected by co-immunoprecipi-
tation, the binding was considerably weaker than that be-
tween p53 and ING1b.
Taken together, these data show that the transcriptional
activities of p63K and p73K were enhanced in the presence
of ING1b. However, both the transcriptional activation and
interaction between p63K/p73K and ING1b were not as robust
as that between p53 and ING1b.
4. Discussion
ING1 has been implicated to play roles in cell cycle arrest,
senescence, and apoptosis. The execution of these antiprolifer-
ative functions of ING1 is mainly attributed to its collabora-
tion with p53. In agreement with the published data that in-
troduction of p53 into H1299 cells induces apoptosis [44], it is
not surprising that the p53/H1299 cells described here were
more sensitive to DNA damage than the parental cells. Cells
expressing ING1b and p53 together grew slower and were
more prone to cell death than cells expressing p53 or
ING1b individually. It was di⁄cult to assess whether
ING1b conferred any additional long-term sensitivity to
DNA damage because cells expressing p53 alone were already
very sensitive to ADR. Our laboratory has recently shown
that transient expression of ING1b increases the cytotoxic
e¡ects of p53 in H1299 cells [16]. We showed that one con-
tributing mechanism involves the inhibition of interaction be-
tween p53 and MDM2 by ING1b, leading to the stabilization
and activation of p53 [16]. Unexpectedly, here we show that
ectopic expression of ING1b in H1299 cells induced a slight
cell cycle delay in the absence of p53 or stress. Moreover,
ING1b alone markedly accentuated the transient cell cycle
arrest induced by ADR, but not by CIS or UV. In our ex-
perimental setup, ING1b was expressed at about ¢ve- to 10-
fold more than the endogenous protein. It would be interest-
ing to see how this induced level of ING1b compares to the
variation of ING1b seen in some cancers, and to the p53-in-
dependent induction of ING1b triggered by UV [10].
The cell cycle delay induced by ING1b appears to be tran-
sient, since clonogenic survival after ADR treatment was not
signi¢cantly a¡ected by ING1b. One possibility is that
ING1b-expressing cells were able to e⁄ciently arrest the cell
cycle after damage, thus they are able to re-enter the cell cycle
after the DNA is subsequently repaired. In contrast, the pro-
pensity of activated p53 to trigger apoptosis after DNA dam-
age may result in the more potent reduction in survival in p53/
H1299 and p53+ING1b/H1299 cells.
It is conceivable that the cell cycle delay triggered by
ING1b in the absence of p53 involves a similar pathway as
p53-dependent arrest. In H1299 cells, expression of ING1a,
ING1b, or ING1c in the absence of p53 does not transacti-
vate p53-responsive promoters like that of MDM2 [16] or
p21CIP1=WAF1 (our unpublished data). A possible explanation
of the cell cycle delay induced by ING1b without p53 is that
Fig. 6. ING1b and p53 a¡ect long-term survival of untreated and
ADR-treated cells. ING1b/H1299, p53/H1299, and p53+ING1b/
H1299 were seeded at 500 cells per plate in the presence of DOX.
The cells were treated with control bu¡er or ADR for 3 h. The cells
were then washed and maintained in medium with or without DOX
until colonies were visible. For samples in lanes 7 and 12, cells were
grown in the absence of DOX for three days before DOX was
added back for the rest of the experiment. The number of colonies
was expressed as a percentage of that grown in the presence of
DOX and without ADR treatment. The means and standard devia-
tions of three independent experiments are shown.
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ING1b may activate other members of the p53, like p63 and
p73. Indeed we found that ING1b can enhance the transcrip-
tional activities of p63K and p73K using the MDM2 promoter
(Fig. 7). Although not as well established as p53, there are
indications that both p63 and p73 are involved in DNA dam-
age responses [45^48]. We have shown that ING1b interacts
with the N-terminal region of p53 [16]. It is noteworthy that
the N-terminal regions are well conserved among members of
the p53 family.
Another possible explanation of the enhancement of ADR-
induced responses by ING1b may be related to its association
with histone acetylation and chromatin remodeling. Acetyla-
tion of histones increases accessibility of chromatin templates,
while deacetylation is frequently linked with chromatin con-
densation and gene silencing. The exact role of ING1 in his-
tone acetylation is not very clear since ING1 has been re-
ported to associate with both HAT and HDAC. The
Saccharomyces cerevisiae ING1-related protein Yng2p is asso-
ciated with HAT activities and components of HAT [22^25].
Human ING1 is able to complement most of the yeast yng2
deletion phenotypes, including the swollen, multibudded mor-
phology and abnormal DNA distribution, and complexes con-
taining human ING1b (but not ING1a) also possess HAT
activity [28]. However, human ING1b was found to be asso-
ciated with the mSin3-containing HDAC [26,27]. It is possible
that ING1b modulated the responses to DNA-damaging
agents like ADR by global or local chromatin remodeling.
It is interesting that the enhancement of cell cycle arrest by
ING1b is speci¢c for ADR but not for CIS or UV. This may
be due to the fact that ADR (a topoisomerase II inhibitor)
and CIS/UV (DNA-crosslinking agents) in£ict di¡erent types
of DNA damages. The responses to the exact type of DNA
damage may be sensitive to the possible role of ING1b in
chromatin remodeling.
In conclusion, we have shown that ING1b can reduce cell
proliferation with p53-dependent and -independent mecha-
nisms. The enhanced sensitivity of both p53-negative and
-positive cancer cells to ADR after ING1b expression suggests
that ING1b may be an attractive target for cancer therapies,
which already has been explored in some studies [15,49].
Acknowledgements: We thank Drs. Daniel Caput, Tim Hunt, Tony
Hunter, Shuntaro Ikawa, Arnold Levine, and Katsumi Yamashita for
generous gifts of reagents. Many thanks are due to members of the
Poon laboratory for comments on the manuscript. This work was
supported in part by the Croucher Foundation, the Philip Morris
Fig. 7. ING1b can activate p53-related proteins. A: Activation of the transcriptional activities of p53-related proteins by ING1b. H1299 cells
were transfected with plasmids expressing an MDM2 promoter-luciferase reporter and L-galactosidase. Control reactions without cotransfection
of other plasmids are shown in experiment 1. Plasmids expressing p73K, p63K, and p53 were cotransfected with control plasmids (experiment
2) or ING1b (experiment 3) as indicated. Cell extracts were prepared, and the luciferase and L-galactosidase activities were determined. The lu-
ciferase activities were normalized with the L-galactosidase activities to correct for transcriptional e⁄ciencies and plotted as a percentage of
p53/p63K/p73K alone. The means and standard deviation of three independent experiments are shown. B: Puri¢cation of recombinant GST-
ING1b. GST-ING1b was expressed in E. coli and puri¢ed as described in Section 2. The puri¢ed protein was applied onto SDS^PAGE and de-
tected by Coomassie blue staining. The positions of molecular mass standards (in kDa) are indicated. C: ING1b can interact with p53 and
p73K. Reticulocyte lysate-expressed p53 and p73K were incubated with either puri¢ed GST or GST-ING1b. The GST fusion proteins were cap-
tured with GSH-agarose and unbound proteins were washed o¡. The coprecipitated p53 and p73K were detected by SDS^PAGE and Phos-
phorImagery. D: ING1b can interact with p53 and p63K. H1299 cells were transfected with plasmids encoding p53 (lanes 1, 2, 5 and 6) or
p63K (lanes 3, 4, 7 and 8) with control vector (odd-numbered lanes) or FLAG-ING1b (even-numbered lanes). Cell-free extracts were prepared
at 24 h after transfection and 100 Wg was subjected to immunoprecipitation with anti-FLAG immune serum. The retained proteins were de-
tected by immunoblotting using antibodies against p53 and p63.
FEBS 27673 9-10-03
F.C. Tsang et al./FEBS Letters 553 (2003) 277^285284
External Research Program, and the Research Grants Council grant
HKUST6129/02M to R.Y.C.P.
References
[1] Garkavtsev, I., Kazarov, A., Gudkov, A. and Riabowol, K.
(1996) Nat. Genet. 14, 415^420.
[2] Saito, A., Furukawa, T., Fukushige, S., Koyama, S., Hoshi, M.,
Hayashi, Y. and Horii, A. (2000) J. Hum. Genet. 45, 177^181.
[3] Garkavtsev, I. (1999) Nat. Genet. 23, 373.
[4] Zeremski, M. et al. (1999) J. Biol. Chem. 274, 32172^32181.
[5] Garkavtsev, I. and Riabowol, K. (1997) Mol. Cell. Biol. 17,
2014^2019.
[6] Helbing, C.C., Veillette, C., Riabowol, K., Johnston, R.N. and
Garkavtsev, I. (1997) Cancer Res. 57, 1255^1258.
[7] Vieyra, D., Toyama, T., Hara, Y., Boland, D., Johnston, R. and
Riabowol, K. (2002) Cancer Res. 62, 4445^4452.
[8] Ha, S., Lee, S., Chung, M. and Choi, Y. (2002) Cancer Res. 62,
1275^1278.
[9] Cheung Jr., K.J., Mitchell, D., Lin, P. and Li, G. (2001) Cancer
Res. 61, 4974^4977.
[10] Cheung Jr., K.J., Bush, J.A., Jia, W. and Li, G. (2000) Br. J.
Cancer 83, 1468^1472.
[11] Scott, M., Boisvert, F.M., Vieyra, D., Johnston, R.N., Bazett-
Jones, D.P. and Riabowol, K. (2001) Nucleic Acids Res. 29,
2052^2058.
[12] Cheung Jr., K.J. and Li, G. (2002) Exp. Cell Res. 279, 291^
298.
[13] Scott, M., Bonne¢n, P., Vieyra, D., Boisvert, F.M., Young, D.,
Bazett-Jones, D.P. and Riabowol, K. (2001) J. Cell Sci. 114,
3455^3462.
[14] Garkavtsev, I., Grigorian, I.A., Ossovskaya, V.S., Chernov,
M.V., Chumakov, P.M. and Gudkov, A.V. (1998) Nature 391,
295^298.
[15] Shinoura, N. et al. (1999) Cancer Res. 59, 5521^5528.
[16] Leung, K.M., Po, L.S., Tsang, F.C., Siu, W.Y., Lau, A., Ho,
H.T. and Poon, R.Y.C. (2002) Cancer Res. 62, 4890^4893.
[17] Nagashima, M. et al. (2001) Proc. Natl. Acad. Sci. USA 98,
9671^9676.
[18] Shimada, Y., Saito, A., Suzuki, M., Takahashi, E. and Horie, M.
(1998) Cytogenet. Cell Genet. 83, 232^235.
[19] Gunduz, M. et al. (2002) Oncogene 21, 4462^4470.
[20] Shiseki, M. et al. (2003) Cancer Res. 63, 2373^2378.
[21] Gozani, O. et al. (2003) Cell 114, 99^111.
[22] Loewith, R., Meijer, M., Lees-Miller, S.P., Riabowol, K. and
Young, D. (2000) Mol. Cell. Biol. 20, 3807^3816.
[23] Howe, L., Kusch, T., Muster, N., Chaterji, R., Yates III, J.R.
and Workman, J.L. (2002) Mol. Cell. Biol. 22, 5047^5053.
[24] Nourani, A., Doyon, Y., Utley, R.T., Allard, S., Lane, W.S. and
Cote, J. (2001) Mol. Cell. Biol. 21, 7629^7640.
[25] Choy, J.S., Tobe, B.T., Huh, J.H. and Kron, S.J. (2001) J. Biol.
Chem. 276, 43653^43662.
[26] Kuzmichev, A., Zhang, Y., Erdjument-Bromage, H., Tempst, P.
and Reinberg, D. (2002) Mol. Cell. Biol. 22, 835^848.
[27] Skowyra, D. et al. (2001) J. Biol. Chem. 276, 8734^8739.
[28] Vieyra, D. et al. (2002) J. Biol. Chem. 277, 29832^29839.
[29] Chen, L. et al. (2001) Cancer Res. 61, 4345^4349.
[30] Gunduz, M., Ouchida, M., Fukushima, K., Hanafusa, H., Etani,
T., Nishioka, S., Nishizaki, K. and Shimizu, K. (2000) Cancer
Res. 60, 3143^3146.
[31] Tokunaga, E., Maehara, Y., Oki, E., Kitamura, K., Kakeji, Y.,
Ohno, S. and Sugimachi, K. (2000) Cancer Lett. 152, 15^22.
[32] Toyama, T. et al. (1999) Oncogene 18, 5187^5193.
[33] Oki, E., Maehara, Y., Tokunaga, E., Kakeji, Y. and Sugimachi,
K. (1999) Cancer Lett. 147, 157^162.
[34] Ohmori, M., Nagai, M., Tasaka, T., Koe¥er, H.P., Toyama, T.,
Riabowol, K. and Takahara, J. (1999) Am. J. Hematol. 62, 118^
119.
[35] Nouman, G.S., Anderson, J.J., Mathers, M.E., Leonard, N.,
Crosier, S., Lunec, J. and Angus, B. (2002) Histopathology 40,
360^366.
[36] Nouman, G.S., Anderson, J.J., Wood, K.M., Lunec, J., Hall,
A.G., Reid, M.M. and Angus, B. (2002) J. Clin. Pathol. 55,
596^601.
[37] Wang, X., Arooz, T., Siu, W.Y., Chiu, C.H., Lau, A., Yamashi-
ta, K. and Poon, R.Y.C. (2001) FEBS Lett. 490, 202^208.
[38] Bodner, S.M. et al. (1992) Oncogene 7, 743^749.
[39] Ausubel, F., Brent, R., Kingston, R., Moore, D., Seidman, J.,
Smith, J. and Struhl, K. (1991) Current protocols in molecular
biology, Wiley, New York.
[40] Poon, R.Y.C., Toyoshima, H. and Hunter, T. (1995) Mol. Biol.
Cell 6, 1197^1213.
[41] Siu, W.Y., Arooz, T. and Poon, R.Y.C. (1999) Exp. Cell Res.
250, 131^141.
[42] Poon, R.Y.C. and Hunter, T. (1995) Science 270, 90^93.
[43] Yam, C.H., Ng, R.W., Siu, W.Y., Lau, A.W. and Poon, R.Y.C.
(1999) Mol. Cell. Biol. 19, 635^645.
[44] Mukhopadhyay, T., Multani, A.S., Roth, J.A. and Pathak, S.
(1998) Oncogene 17, 901^906.
[45] Gong, J.G., Costanzo, A., Yang, H.Q., Melino, G., Kaelin Jr.,
W.G., Levrero, M. and Wang, J.Y. (1999) Nature 399, 806^809.
[46] Agami, R., Blandino, G., Oren, M. and Shaul, Y. (1999) Nature
399, 809^813.
[47] Yuan, Z.M. et al. (1999) Nature 399, 814^817.
[48] Katoh, I., Aisaki, K.I., Kurata, S.I., Ikawa, S. and Ikawa, Y.
(2000) Oncogene 19, 3126^3130.
[49] Shimada, H. et al. (2002) Oncogene 21, 1208^1216.
FEBS 27673 9-10-03
F.C. Tsang et al./FEBS Letters 553 (2003) 277^285 285
